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ABSTRACT 
 
Background: Survival and quality of life for patients on hemodialysis remain poor despite 
substantial research efforts. Existing trials often report surrogate outcomes that may not be relevant 
to patients and clinicians. The aim of this project was to generate a consensus-based, prioritized list 
of core outcomes for trials in hemodialysis.  
 
Study Design: In a Delphi survey, participants rated the importance of outcomes using a 9-point 
Likert scale in round 1 and then re-rated outcomes in rounds 2 and 3 after reviewing other 
respondents’ scores. For each outcome, the median, mean, and proportion rating 7-9 (critically 
important) were calculated. 
 
Setting and Participants: 1,181 participants (202 [17%] patients/caregivers, 979 health 
professionals) from 73 countries completed round 1, with 838 (71%) completing round 3. 
 
Outcomes and Measurements: Outcomes included in the potential core outcome set met the 
following criteria for both patients/caregivers and health professionals: median score ≥8; mean 
score ≥7.5; proportion rating the outcome ‘critically important’ ≥75% and median score <10 in the 
forced ranking question. 
 
Results: Patients/caregivers rated four outcomes higher than health professionals: ability to travel 
(mean difference 0.9), dialysis-free time (0.5), dialysis adequacy (0.3), and washed out after dialysis 
(0.2). Health professionals gave a higher rating for mortality (1.0), hospitalization (1.0), drop in 
blood pressure (1.0), vascular access complications (0.9), depression (0.9), cardiovascular disease 
(0.8), target weight (0.7), infection (0.4) and potassium (0.4). 
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Limitations: The Delphi survey was conducted online in English-language and excludes 
participants without access to a computer and internet connection.  
 
Conclusions: Patients/caregivers gave higher priority to lifestyle-related outcomes than health 
professionals. The prioritized outcomes for both groups were vascular access problems, dialysis 
adequacy, fatigue, cardiovascular disease and mortality. This process will inform a core outcome set 
that in turn will improve the relevance, efficiency and comparability of trial evidence to facilitate 
treatment decisions. 
  
Keywords: hemodialysis, outcomes, Delphi survey, core outcome set, trials, outcome domains 
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INTRODUCTION 
 
The enormous investment in biomedical research, particularly in randomized trials, may not have 
led to the improvements in health that were hoped for. 1-3 It has been estimated that 85% of the 
worldwide US $240 billion invested in research annually is wasted.3 In nephrology, there has been 
substantial research investment into hemodialysis (HD), yet survival rates have not improved 
correspondingly over the past 40 years and quality of life remains poor even compared with patients 
with many cancers.4-7 This may be partly attributable to what outcomes are selected and reported in 
trials – a challenge well-recognized across medical specialties.1,8-10 
 
Surrogate endpoints are frequently used in clinical trials because of feasibility, in preference to 
outcomes that are directly relevant to patients and clinicians.9,11,12 In HD, biochemical markers such 
as serum phosphorus, calcium, and parathyroid hormone, are commonly reported but are not 
strongly and consistently associated with mortality, cardiovascular disease (CVD), or quality of 
life.13-17 Patients on HD prioritize outcomes relevant to their well-being and lifestyle – fatigue, 
ability to travel, ability to work, sleep, anxiety/stress 18,19 – all largely absent as outcomes reported 
by HD trials. In addition, the large heterogeneity of outcome measures and potential for outcome 
reporting bias (where trials selectively report results for outcomes that favor the intervention) 
undermines the reliability of trial evidence to inform clinicians and patients about the relative 
effects of interventions.20 
 
Engaging all stakeholders in establishing a core outcome set, an agreed minimum set of 
standardized outcomes to be measured and reported in all trials for a specific clinical area 21,22, can 
increase the relevance, efficiency and reliability of trials. Initiatives to develop core outcomes are 
seen in rheumatology and oncology, and have demonstrated improvements in consistent reporting 
of relevant outcomes.10,23,24 As part of the international Standardized Outcomes in Nephrology-
Hemodialysis (SONG-HD) initiative, this study aimed to generate a consensus-based prioritized list 
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of outcome domains for people on HD, which will be used to establish a core outcome set that 
reflects the shared priorities of patients, caregivers and health professionals.  
 
METHODS 
 
Study design 
 
The Delphi method is a technique for achieving consensus among a panel of experts. This process 
involves sequential surveys, typically conducted over three rounds, answered anonymously and 
gives equal influence to all who participate. It was first developed by the RAND Corporation in the 
1950’s 25 and has since been increasingly used as a valid approach to develop consensus-based core 
outcomes for clinical trials in various medical specialty areas.10,22,26-28 The SONG-HD Delphi 
process is shown in Supplementary Figure S1. 
 
Participant selection and recruitment  
 
Stakeholders including patients, caregivers/family members, nephrologists, surgeons, nurses, social 
workers, psychologists, dieticians, pharmacists, policy makers, researchers and industry, with 
experience or interest in HD were invited to join the Delphi Panel. Participants worldwide were 
eligible if they were aged over 18 years and able to complete an online survey in English-language. 
All participants provided informed consent. 
  
Using an opt-in, snowballing sampling frame, we recruited patients/caregivers through participating 
hospitals, patient/consumer organizations, and social media listed in Supplementary File S1. Health 
professionals were recruited via the investigators networks and via emails and newsletters circulated 
by professional societies (Supplementary File S1). Participants registered their email on 
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www.songinitiative.org prior to the survey launch. The ethics boards of the University of Sydney 
(2015/228), Baylor College of Medicine (H-37406), University of Calgary (REB15-0708), Monash 
Medical Centre (13082B), Salford Royal NHS (15/WM/0303), and Sydney West Area Health 
Service (HREC2009/6/4.15) approved this study. 
 
Data collection 
 
The 34 outcome domains for the three-round Delphi survey were identified from a systematic 
review of outcomes reported in trials in HD, stakeholder interviews, and nominal group technique 
conducted with patients on HD and caregivers.29,30 The ordering of outcomes was randomized and 
included a plain language definition (Supplementary File S2). The survey was reviewed by the 
SONG Executive Committee and SONG-HD investigators and piloted among 10 patients. The 
Delphi survey was completed online via LimeSurvey between September and November, 2015. The 
online survey administration minimizes data entry error, allows for wider dissemination and is more 
efficient compared to a paper survey. 
 
Round 1: Participants rated the importance of each of the 34 outcomes based on a 9-point Likert 
scale. A score of 7-9 indicated that the outcome was of “critical importance”, 4-6 indicated 
“important but not critical” and 1-3 indicated “limited importance” according to the GRADE 
process.31 An option of “unsure” was provided. Participants could enter comments about their 
choice of ranking for each outcome. In addition, participants could suggest new outcomes that were 
not included in the survey. Outcomes with a mean and median of less than 7 for patients/ caregivers 
and health professionals were not included in round 2.  
  
Round 2: Participants reviewed the group scores and their own score for each outcome and re-rated 
the 29 outcomes using the same 9-point Likert scale. The group scores were displayed in an 
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interactive column graph which showed the distribution of scores for: patients/caregivers, health 
professionals, and the total sample combined (weighted) (Supplementary Figure S1). Instructions 
on how to read the graph were provided to ensure that participants were able to understand the 
results. For each outcome, an optional comments box allowed participants to explain reasons for 
their rating. Outcomes with a mean and median ≤ 7 for patients/ caregivers and health professionals 
were excluded from round 3. 
 
Round 3: Participants were asked to re-rate 20 outcomes using the same Likert scale in the previous 
rounds after viewing the scores, and in addition, de-identified comments (i.e. free text responses 
from participants relating to reasons for their rankings or observations on the results for each 
outcome) from round 2. The comments were divided into two boxes: ‘Patients and caregivers’ and 
‘Health professionals’ with the ability to scroll down and read all comments. A free text box was 
provided for each outcome so participants could provide additional comments. In addition, 
participants completed a forced ranking question, using a drag and drop function, to rank outcomes 
relative to each other. 
 
Data analysis  
 
We used SPSS (IBM; Version 22.0) to calculate descriptive statistics. We calculated the median, 
mean, and proportion of participants (rating 7-9) for each outcome. The scores were calculated 
separately for patients/caregivers and health professionals, with the difference in means considered 
significant at P<0.05 based on the t-test. For the ranking scores, we calculated the median and 
interquartile range (IQR) for each outcome to determine rank. Any analysis of the total sample was 
weighted equally between patients/caregivers and health professionals. 
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Consensus was defined a priori based on the OMERACT definition using proportion scores. 
“Consensus in” is defined as greater than or equal to 70% of participants scoring as 7 to 9 and less 
than 15% participants scoring as 1 to 3.29 However, as most participants rated all outcomes in round 
3 as critically important with scores of 7-9, these criteria resulted in a list of 16 outcomes, which 
exceeded the recommended 3 to 5 outcomes for a core outcome set. Therefore, the definition and 
threshold for “consensus in” were revised to determine a maximum of five core outcomes to be 
considered for the core outcome set.  
 
Definition of consensus 
 
Outcomes from round 1 with a mean and median score greater than or equal to 7 for 
patients/caregivers and health professionals were included in round 2. This was validated against 
the proportion of critically important scores (rated 7-9) for each outcome to ensure that important 
outcomes were not excluded. 
 
Outcomes from round 2 with a mean and median score greater than 7 for patients/caregivers and 
health professionals were included in round 3. This was validated against the proportion of critically 
important scores (rated 7-9) for each outcome. 
 
Outcomes included in the potential core outcome set met the following criteria for both 
patients/caregivers and health professionals: median score greater than or equal to 8; mean score 
greater than or equal to 7.5; proportion of participants rating the outcome ‘critically important’ is 
greater than or equal to 75% and median score is less than 10 in the forced ranking question. 
 
RESULTS 
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Participant characteristics 
 
In total, 1 181 people from 73 countries participated in round 1 of the Delphi survey including 202 
(17%) patients/caregivers and 979 (83%) health professionals. Round 2 included 165 
patients/caregivers (17%) and 784 health professionals (83%) from 63 countries. In the third and 
final round, 150 patients/caregivers (18%) and 688 health professionals (82%) participated. The full 
survey completion rate was 71%. The participant characteristics are provided in Tables 1 and 2.  
 
In round 3, 115 (77%) patients/caregivers were aged from 41 to 70 years and 76 (51%) were 
women. Patients/caregivers were from 14 countries in round 1 (11 countries in round 3). In round 3, 
the majority of patient/caregiver participants were from Australia (40 [27%]), Canada (37 [24.7%]), 
United Kingdom (UK) (25 [17%]), United States (US) (19 [13%]), and New Zealand (18 [12%]). 
Among the 116 (77%) patients on HD, 63 (42%) patients were on in-center HD and 51 (34%) were 
on home HD. The health professionals included 857 nephrologists (51%), 386 nurses (38%), 53 
researchers (5%), and 63 (6%) in other roles. Health professionals were from 72 countries in round 
1 (62 countries in round 3).  
 
Delphi scores 
 
Round 1: The means, medians, and proportion of participants rating the outcome 7 – 9 (critical 
importance) for each of the 34 outcomes are shown in Supplementary Table S1. The top three 
outcomes rated by patients/caregivers based on mean scores (1 to 9) were: dialysis adequacy (7.5 
[standard deviation [SD] =2.1]), ability to travel (7.5 [SD 1.9]) and dialysis-free time (7.3 [SD 1.8]). 
The top three outcomes for health professionals were: vascular access problems (8.1 [SD 1.3]), 
CVD (7.9 [SD 1.3]), and mortality (7.7 [SD 1.6]. Definitions of high rating outcomes are provided 
in Box 1. 
12 
 
 
The following outcomes were excluded from round 2 as they had a mean or median score of less 
than 7 (not of critical importance) among both patient/caregiver and health professional groups in 
round 1: nausea/vomiting, sexual function, restless legs syndrome, itching and cramps. Less than 
25% of participants suggested new outcomes in round 1 (Supplementary Table S2). These outcomes 
were not considered for inclusion in round 2 due to the following reasons: the outcome could not be 
measured in a clinical trial for the majority of adult patients on HD, the outcome was too broad 
conceptually or ambiguously defined, and the outcome was described as an intervention.  
 
Round 2: Round 2 included 29 outcomes (Supplementary Table S3). The top 3 outcomes for 
patients/caregivers were: dialysis adequacy (7.7 [SD 1.8]), ability to travel (7.6 [SD 1.9]) and 
dialysis-free time (7.5 [SD 1.7]). The top 3 outcomes rated by health professionals were: vascular 
access problems (8.4 [SD 1.0]), CVD (8.2 [SD 1.1]) and mortality (8.2 [SD 1.2]). 
 
Outcomes which had a mean and median score ≤7 with less than 70% of the sample rating the 
outcome 7-9 (critical importance) were excluded from round 3: anxiety/stress, food enjoyment, 
calcium, parathyroid hormone, cognition, sleep, bone health, financial impact and phosphate.  
 
Round 3: Round 3 included 20 outcomes (Supplementary Table S4). The top three outcomes for 
patients/caregivers were: dialysis adequacy (7.9 [SD 1.8]), ability to travel (7.7 [SD 1.7]) and 
vascular access problems (7.7 [SD 2.0]). The top three outcomes for health professionals were 
vascular access problems (8.6 [SD 0.9]), CVD (8.4 [SD 1.0]) and mortality (8.3 [SD 1.1]).  
 
Outcomes that met at least two of the following criteria for consensus within both stakeholder 
groups (median ≥ 8, mean ≥ 7.5, proportion ≥ 75%, and median rank < 10) [Table 3]) were: CVD, 
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mortality, dialysis adequacy, fatigue, and vascular access problems. All participant comments for 
each outcome are provided in Supplementary File S3. 
 
Changes in scores from round 1 to 3 within stakeholder groups 
 
As shown in Figure 1, the patient/caregiver mean scores increased between rounds 1 and 3 for the 
following 7 outcomes: vascular access problems (mean score difference 0.9, P = <0.001), CVD 
(0.7, P = 0.002), infection/immunity (0.7, P = 0.004), drop in blood pressure (0.6, P = 0.02), 
mobility (0.6, P = 0.02), target weight (0.6, P = 0.02) and washed out after dialysis (0.5, P = 0.01).  
 
For health professionals, the mean scores increased for 16 outcomes between rounds 1 and 3 
(Figure 2): mortality (0.6, P <0.001), CVD (0.5, P < 0.001), vascular access problems (0.4, P < 
0.001), ability to travel (0.4, P < 0.001), dialysis-free time (0.4, P < 0.001), dialysis adequacy (0.4, 
P < 0.001), washed out after dialysis (0.3, P <0.001), ability to work (0.3, P < 0.001), 
infection/immunity (0.3, P < 0.001),  drop in blood pressure (0.3, P < 0.001), hospitalization (0.3, P 
< 0.001), fatigue (0.3, P < 0.001), impact on family/friends (0.3, P < 0.001), mobility (0.2, P < 
0.001), pain (0.2, P = 0.007) and blood pressure (0.2, P = 0.02). No mean scores decreased across 
the three rounds of the survey for either patients/caregivers or health professionals. 
 
Differences between stakeholder groups 
 
The differences in ratings between stakeholder groups are shown in Figure 3. Based on the 
difference in mean scores in round 3, four outcomes were rated higher by patients/caregivers: 
ability to travel (mean difference 0.9, P <0.001), dialysis-free time (0.5, P <0.001), dialysis 
adequacy (0.3, P = 0.05) and washed out after dialysis (0.2, P = 0.05). 
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Health professionals rated 11 outcomes higher compared to patients/caregivers: mortality (mean 
difference 1.0, P <0.001), hospitalization (1.0, P <0.001), drop in blood pressure (1.0, P <0.001), 
vascular access problems (0.9, P <0.001), depression (0.9, P <0.001), CVD (0.8, P <0.001), target 
weight (0.7, P <0.001), infection/immunity (0.4, P = 0.002), potassium (0.4, P = 0.02), ability to 
work (0.3, P = 0.008), and pain (0.3, P = 0.04). 
 
Forced ranking scores 
 
The results of the forced ranking question are shown in Supplementary Table S5. The top outcomes 
ranked by patients/caregivers were (median rank score [Inter Quartile Range (IQR)]): CVD (7 [IQR 
4-14]), vascular access problems (median rank 7 [IQR 3-13]), dialysis adequacy (8[IQR 4-11]) and 
fatigue (8 [IQR 4-11]). The top outcomes ranked by health professionals were: CVD (3 [IQR 2-7]), 
mortality (3 [IQR 1-9]) and vascular access problems (4 [IQR 2-7]).  
 
DISCUSSION 
 
The highest-priority outcomes shared among patients/caregivers and health professionals were 
vascular access problems, dialysis adequacy, fatigue, CVD, and mortality. Overall, most of these 
reflect common and high-impact outcomes in the context of HD, which have remained as major 
challenges in providing care for patients on HD. Frequently reported biochemical outcomes in HD 
trials, such as phosphate, calcium and parathyroid hormone, were consistently rated to be of lower 
importance by both stakeholder groups.   
 
Although there was convergence in ratings between patients/caregivers and health professionals 
across the three rounds of the Delphi, our findings also highlight some mismatches. Outcomes 
relating to lifestyle (ability to travel, dialysis-free time) and well-being (washed out after dialysis) 
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rated higher among patients/ caregivers compared to health professionals. Research has consistently 
shown that patients and caregivers prioritize lifestyle-related outcomes over biochemical 
endpoints.18,19,30 Ability to travel, fatigue/energy and dialysis-free time are important outcomes for 
patients and caregivers who want to retain normality in their day to day lives and maintain a 
reasonable quality of life.19,30 In a recent discrete choice study, patients were willing to trade off 23 
months of life expectancy with home-based dialysis to increase their ability to travel.32 Biochemical 
endpoints are less important to patients and caregivers because they are considered intangible or 
imperceptible.30 
 
Dialysis adequacy was also rated higher by patients/caregivers. The participant comments 
(Supplementary File S3) and discussions from the recent SONG-HD consensus workshop on 
establishing core outcomes in HD33, indicates participants conceptualized the term “dialysis 
adequacy” as a broad quality of life outcome (i.e. dialysis that is adequate for enabling patients to 
feel well) rather than quantification of urea kinetics, which may explain this apparent divergence.   
 
The rating of CVD by patients increased significantly between round 1 and 3. Based on the 
comments provided by patients shown in Supplementary File S3, the reasons were largely due to 
gaining an understanding of the importance of CVD through reading other participant’s comments, 
and a few patients who experienced cardiovascular events during the survey period (Supplementary 
File S3). Similarly, studies have shown that patients with chronic kidney disease have limited 
knowledge about their risk of CVD.30,34 
 
The outcomes rated higher by health professionals (with a mean difference greater than 0.5 in 
ratings) were: mortality, hospitalization, drop in blood pressure, vascular access problems, 
depression, CVD, and target weight. This perhaps reflects their perceived primary clinical role in 
preventing and managing these outcomes which are common among HD patients and awareness of 
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their impact on patients’ lives, whereas high-priority outcomes for patients such as ability to travel 
and dialysis-free time may be seen by health professionals as impractical to measure. 
 
Uremic symptoms such as itching and nausea/vomiting, as well as restless legs syndrome and 
cramps were rated relatively lower by patients/caregivers in round 1 and were excluded from 
subsequent rounds. Instead, patients/caregivers gave higher priority to broader outcomes related to 
lifestyle impact and overall well-being (dialysis-free time, ability to travel, fatigue) rather than 
specific symptoms. Yet, many patient-reported outcome measures are designed to assess symptoms 
and few robust and well-validated instruments measure specific patient-important outcomes that 
have an arguably more pervasive and long-term impact on lifestyle and well-being.35-37 
Furthermore, patients may not report lifestyle problems (e.g. ability to work) which are not 
articulated in clinical settings as patients may perceive these to be beyond their clinician’s control. 
 
The SONG-HD Delphi survey had a large sample size (five times greater than most similar Delphi 
surveys to establish core outcomes)23,38,39 and achieved a broad engagement of a range of 
stakeholders including patients/caregivers, multidisciplinary healthcare providers, policy makers 
and industry, across 73 countries, and retained a high response rate of 71% by round 3. The process 
provided a transparent and systematic way to gain consensus on the importance of outcomes to 
consider for a core outcome set in HD. However, there are some potential limitations. The Delphi 
survey was conducted online and excludes participants without access to a computer and internet 
connection. The survey was only available in English-language to retain consistency of meaning 
and for feasibility, although some participants submitted open-text responses in Spanish-language 
which were translated. We also acknowledge that detailed analysis of the open-text responses was 
not conducted and is beyond the scope of the current paper. Given the design of the Delphi survey, 
we recognize that the results are potentially biased towards participants who are English speaking 
with access to a computer and internet connection, and who have the ability to use a computer. 
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We included participants from 73 countries and acknowledge that the majority of participants were 
from high income countries. We recognize that these outcomes may not be shared by those who did 
not participate in the study, or by individuals or groups within the study. A study of this type must 
necessarily accept the views of the majority of participants as representing the consensus position, 
and will not represent the view of all individuals. 
 
Whilst definitions were provided for each outcome domain, we acknowledge the inevitable 
interaction between some outcome domains, and participants may have interpreted the outcomes 
differently. We provided the participant comments to make explicit how the outcomes were 
conceptualized, and based on these data, we did not note any apparent differences that may have 
explained variation in prioritization between patients/caregivers and health professionals. The 
results from the consensus workshop further support this.33 
 
Currently, there is no core outcome set in chronic kidney disease. The Delphi survey results will be 
used to establish a core outcome set to be reported in all trials in HD, which is expected to increase 
the quality and relevance of research. This has been done successfully by the Outcome Measures in 
Rheumatology (OMERACT) initiative, which has improved the reporting and relevance of 
outcomes in rheumatology trials.10,24 Recent analyses have shown that a higher percentage of trials 
are now incorporating the OMERACT core outcome set in rheumatology trials.24 
 
The results of this study were discussed at a recent SONG-HD consensus workshop. To effectively 
implement a core outcome set in chronic kidney disease, patients/caregivers and health professional 
participants suggested that outcome measures should be feasible and valid, and take patient 
priorities into account.33 Once the core outcome domains have been established, which will be 
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largely informed by the results of this Delphi survey, further work will focus on identifying core 
outcome measures for the outcome domains. 
 
In summary, the international SONG-HD Delphi study identified a prioritized set of outcome 
domains for trials in HD based on consensus among key stakeholder groups. The top prioritized 
outcomes by both patients/caregivers and health professionals were vascular access problems, 
dialysis adequacy, fatigue, CVD and mortality. Patients/caregivers place highest value on outcomes 
that will enable them to maintain their day-to-day well-being and lifestyle. The findings will 
directly inform the development of a core outcome set to be used in HD trials. Ultimately, this will 
strengthen the relevance and reliability of trial evidence to support shared decision-making for 
people dependent on HD in order to improve treatment outcomes. 
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Note: Ordered by round 3 scores. Round 1 (n=979); round 2 (n=784); round 3 (n=688). Mean 
scores for round 2 and 3 are not available for outcomes that were excluded in those rounds. 
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Table 1. Characteristics of patients/caregivers 
 
Characteristic 
n (%) 
Round 1 
n=202 
Round 2 
n=165 
Round 3 
n=150 
Participant type    
 Patient 168 (83.2) 138 (83.6) 127 (84.7) 
 Caregiver/family member 34 (16.8) 27 (16.4) 23 (15.3) 
    
Gender    
 Male 96 (47.5) 78 (47.3) 74 (49.3) 
 Female 106 (52.5) 87 (52.7) 76 (50.7) 
    
Age group (years)    
 18 – 40  33 (16.4) 23 (13.9) 16 (10.7) 
 41 – 50 41 (20.3) 34 (20.6)    29 (19.3) 
 51 – 60 59 (29.2) 49 (29.7)       47 (31.3) 
 61 – 70  48 (23.8) 40 (24.2)       39 (26.0) 
 ≥ 71 21 (10.4) 19 (11.5) 19 (12.7) 
    
Marital status*    
 Single 24 (11.9)  20 (12.1)  17 (11.3) 
 Partner/de-facto 14 (7.0) 11 (6.7) 9 (6.5) 
 Married 110 (54.5)   87 (52.7)   78 (52.0)   
 Divorced/separated/widowed          41 (20.3) 34 (20.6) 34 (24.6) 
    
Number of children*    
 0 64 (31.7) 51 (30.9) 43 (28.7) 
 1-2 83 (41.1) 66 (40.0) 63 (42.0) 
 3-4 41 (20.3) 34 (20.6) 31 (20.7) 
    
Employment status*    
 Employed 74 (36.7) 55 (33.3) 46 (35.4) 
 Unemployed 37 (18.3)  28 (17.0)  25 (16.7)   
 Retired 67 (33.2)  60 (36.4)  58 (38.7)   
 Student  1 (0.5)  1 (0.6)  1 (0.8) 
    
Education*    
 Did not complete high school 28 (13.9) 21 (12.7) 18 (12.0) 
 High school graduate 29 (14.4)  22 (13.3)  22 (14.7) 
 Professional certificate 43 (21.3)  36 (21.8)  32 (21.3) 
 Undergraduate degree 59 (29.2)  47 (28.5)       43 (28.7) 
 Postgraduate degree 24 (11.9)   22 (13.3)      19 (12.7) 
    
Current type of treatment*    
 In center hemodialysis 91 (45.0)  71 (43.0)  63 (42.0) 
 Home hemodialysis 70 (34.7)   57 (34.5)   51 (34.0)    
 Peritoneal dialysis 2 (1.0)   2 (1.2)   2 (1.3)   
 Transplant 19 (9.4) 17 (10.3) 17 (11.3) 
    
Years on hemodialysis*    
 < 1 26 (12.9)  18 (10.9)  17 (11.3) 
 1-5 95 (47.0)   76 (46.1)  69 (46.0)   
 6-10 27 (13.4)     25 (15.2)   22 (14.7)     
 11-15 20 (9.9)    17 (10.3)   14 (9.3)   
 > 15 15 (7.4)     12 (7.3)   12 (8.0) 
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Country    
 Canada 53 (26.2)   41 (24.8) 37 (24.7) 
 Australia 49 (24.3)  41 (24.8) 40 (26.7) 
 United Kingdom 35 (17.3)                                           29 (17.6) 25 (16.7) 
 United States 25 (12.4) 20 (12.1) 19 (12.7) 
 New Zealand 21 (10.4)   20 (12.1) 18 (12.0) 
 Othera 19 (9.5) 14 (8.4) 11(7.3) 
 
*Percentages do not add to 100 due to undisclosed responses (excluded). 
aOther includes 9 countries: Romania, India, Spain, Czech Republic, Egypt, 
Netherlands, Indonesia, Italy and Philippines. 
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Table 2. Characteristics of health professionals 
 
Characteristic 
n (%) 
Round 1 
n=979 
Round 2 
 n=784 
Round 3 
 n=688 
Participant typea        
 Nephrologist 483 (46.9) 450 (57.4) 401 (58.3) 
 Nurse 386 (37.5) 277 (35.3) 233 (33.9) 
 Researcher 53 (5.2) 50 (6.4) 47 (6.8) 
 Nephrology trainee  44 (4.3) 36 (4.3) 28 (3.8) 
 Policy maker 17 (1.7) 16 (1.9) 16 (2.2) 
 Industry  13 (1.3) 13 (1.6) 12 (1.6) 
 Dietician 11 (1.1) 9 (1.1) 9 (1.2) 
 Social worker 7 (0.7) 7 (0.8) 7 (1.0) 
 Pharmacist 4 (0.4) 3 (0.4) 3 (0.4) 
 Psychologist 3 (0.3) 1 (0.1) 1 (0.1) 
 Surgeon 2 (0.2) 2 (0.2) 2 (0.3) 
 Other 6 (0.6) 3 (0.4) 3 (0.4) 
    
Gender    
 Male 447 (45.7) 362 (46.2) 318 (46.2) 
 Female 532 (54.3) 422 (53.8) 370 (53.8) 
    
Age group (years)    
 18 - 40  435 (44.4) 317 (40.4) 268 (39.0) 
 41 – 50 262 (26.8) 220 (28.1) 197 (28.6) 
 51 – 60 207 (21.1) 181 (23.1) 164 (23.8) 
 61 – 70  63 (6.4) 58 (7.4) 52 (7.6) 
 ≥ 71 12 (1.2) 8 (1.0) 7 (1.0) 
    
Experience in HD (years)    
 ≤10 406 (41.5)  297 (37.9)  252 (36.6)    
 11-20 308 (31.5)  254 (32.4)  228 (33.1) 
 ≥ 21 265 (27.1) 117 (29.7) 63 (9.1) 
    
No. of hemodialysis trials as investigator   
 0 439 (44.8)  336 (42.9)  287 (41.7)    
 1-5 364 (37.2)   299 (38.1)  266 (38.7)   
 6-10 93 (9.5)   80 (10.2)   72 (10.5)     
 ≥ 11 83 (8.5) 69 (8.8) 63 (9.2) 
    
Other roles  
 Government, policy  119 (10.9) 93 (10.6) 87 (11.2) 
 Guidelines  391 (35.8) 314 (35.6) 278 (35.6) 
 Funding  73 (6.7) 66 (7.5) 60 (7.7) 
 Other 509 (46.6) 408 (46.3) 355 (45.5) 
    
Country    
 Australia 133 (13.6) 120 (15.3) 108 (15.7) 
 Saudi Arabia 131 (13.4) 83 (10.6) 66 (9.6) 
 Spain 122 (12.5) 98 (12.5) 85 (12.4) 
 Romania 101 (10.3) 73 (9.3) 59 (8.6) 
 Canada 58 (5.9) 48 (6.1) 42 (6.1) 
 Portugal 56 (5.7) 48 (6.1) 44 (6.4) 
 United Kingdom 49 (5.0) 45 (5.7) 41 (6.0) 
 United States 35 (3.6) 30 (3.8) 29 (4.2) 
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 New Zealand 30 (3.1) 26 (3.3) 23 (3.3) 
 Turkey 21 (2.1) 13 (1.7) 12 (1.7) 
 Otherb 243 (24.7) 213 (25.5) 179 (26.0) 
 
aSome have multiple roles. 
bOther includes 63 countries: Philippines , India , Belgium , Germany , Italy , 
Netherlands , Poland , Hungary , Argentina , Egypt , Greece , Sweden , Thailand , 
France , China , Croatia , Lithuania , Russian Federation , Singapore , Bangladesh , 
Brazil , Chile , Israel , Nigeria , Syria , Uruguay , Colombia , Czech Republic , Ireland 
(Republic) , Japan , Kuwait , Malaysia , Mexico , Pakistan , Serbia , Slovakia , 
Slovenia , South Africa , Switzerland , Armenia , Austria , Belarus , Bolivia , Bosnia 
Herzegovina , Cameroon , Chad , Denmark , El Salvador , Indonesia , Iran , Korea 
South , Lebanon , Macedonia , Malawi , Morocco , Niger , Oman , Paraguay , Peru , 
Senegal , Venezuela , Vietnam , Yemen. 
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Box 1. Definitions of high rating outcome domains 
 
Outcome domain Definition 
Vascular access problems 
Problems with fistula, graft, or catheter required for 
dialysis e.g. access infections, bleeding, bruising, pain, 
discomfort, clotting 
Death/Mortality 
Number of people on hemodialysis who have died, risk 
of death, how long the patient will live 
Cardiovascular disease 
Disease of the heart and blood vessels e.g. heart 
attack, stroke, blockage of blood vessels 
Dialysis adequacy How well the dialysis cleans the blood, clearance, Kt/V 
Fatigue/Energy 
Feeling tired with no energy for weeks, for most of the 
time 
Ability to travel To go away for holiday, event, visiting family, work 
Dialysis-free time Time (hours/days) not doing dialysis 
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Table 3. Inclusion criteria for the core outcome set based on median, mean, proportion (7-9) and median rank scores 
  
  
Median score ≥ 8 Mean score  ≥ 7.5 
 Proportion % 7-9 score 
(critically important)  
≥ 75% 
Median rank  
(forced rank question) 
  
Patients/ 
caregivers 
Health 
professionals 
Patients/ 
caregivers 
Health 
professionals 
Patients/ 
caregivers 
Health 
professionals 
Patients/ 
caregivers 
Health 
professionals 
 
Core outcome set: 
Outcomes appear 
consistently (at least 
twice) across all 
measures for both 
groups 
Vascular access 
problems 
9.0 9.0 7.7 8.6 82 97 7.0 4.0 
Death/mortality 9.0 9.0 7.3 8.3 73 94 8.5 3.0 
Cardiovascular disease 8.0 9.0 7.6 8.4 77 95 7.0 3.0 
Dialysis adequacy 9.0 8.0 7.9 7.6 90 81 8.0 11.0 
Fatigue 8.0 8.0 7.6 7.6 82 86 8.0 11.0 
Outcomes do not 
appear consistently (at 
least twice) across all 
measures for both 
groups 
Ability to work 8.0 8.0 7.3 7.7 74 85 9.0 13.0 
Drop in blood pressure 8.0 8.0 6.9 7.9 68 89 11.0 9.0 
Ability to travel 8.5 7.0 7.7 6.8 75 57 10.0 17.0 
Dialysis-free time 8.0 7.0 7.6 7.1 74 67 9.0 15.0 
Infection/immunity 7.0 8.0 7.2 7.6 74 86 11.0 9.0 
Anaemia 8.0 7.0 7.4 7.3 77 76 11.0 10.0 
Mobility 8.0 7.0 7.3 7.2 76 71 11.0 14.0 
Blood pressure 8.0 7.0 7.4 7.3 76 81 10.0 9.0 
Washed out after dialysis 8.0 7.0 7.5 7.2 80 78 10.0 13.0 
Hospitalisation 7.0 8.0 6.6 7.6 65 86 13.0 8.0 
Impact on family/friends 7.0 7.0 7.1 7.2 66 72 11.0 15.0 
Depression 7.0 7.0 6.4 7.2 61 79 13.0 12.0 
Target weight 7.0 7.0 6.6 7.2 58 78 13.0 11.0 
Potassium 7.0 7.0 6.7 7.1 63 69 13.0 11.0 
Pain 7.0 7.0 6.9 7.2 66 75 13.0 12.0 
 
Note: Grey shading indicates that the outcome met the criteria. I.e. the outcome rates consistently high, according to the inclusion criteria, for both patients/caregivers and health 
professionals. The outcome must appear at least twice for each of the criteria (median ≥ 8, mean ≥ 7.5, proportion ≥ 75%, and median rank < 10).  
 
